BackgroundHepatitis C virus is becoming a significant causative factor in the aetiology of chronic liver disease worldwide.
INTRODUCTION
Chronic liver disease (CLD) is a disease of the liver resulting from an inflammatory, infiltrative, immunologic, mechanical or metabolic injury to the liver, which has persisted for six or more months without complete resolution. 1 Hepatitis C virus (HCV) has become a leading cause of CLD worldwide. 2 Approximately 3% of the world population, 170 million people, are chronically infected by HCV. The prevalence of chronic HCV ranges from 0.1 to 5% in different countries. 3, 4, 5 In industrialized countries, HCV accounts for 20% of cases of acute hepatitis, 70% of cases of chronic hepatitis, 40% of cases of end-stage cirrhosis, 60% of cases of hepatocellular carcinoma (HCC) and 30% of cases of liver transplants. 6, 7 Other causes of CLD are viral hepatitis (hepatitis B and D, cytomegalovirus, Epstein Barr virus), toxoplasmosis, schistosomiasis, inherited and metabolic disorders, drugs and toxins etc. 8 Information on the prevalence of HCV infection in CLD is scanty in Nigeria especially from the North-eastern region. We, therefore, determined the prevalence of HCV infection in Nigerians with CLD.
PATIENTS AND METHODS
The study was carried out at the Their biodata was obtained. Written informed consent was obtained from each patient. Serum samples of all enrolees were screened for HCV using rapid test ELISA kits (Acon Laboratories, USA) to detect antibodies to hepatitis C virus (anti-HCV).
ANALYSIS
The data obtained were analysed using Epi-info version 6 statistical software. Chi-squared was used to test association between discrete variables. The level of statistical significance was set at p is equal to or less than 0.05.
RESULTS
A total of 90 patients with clinical, biochemical and sonographic evidence of chronic liver disease were studied. Histological confirmation of CLD was done by aspiration/ percutaneous liver biopsy in 56 patients.
AGE
The age of the patients ranged between 18 and 75 years with an average of 33.3 and 36.3years for the cases and controls respectively.
SEX
The study group comprised 59(65.6%) males and 31(34.4%) females. The control group comprised 57(67.1%) males and 28(32.9%) females. There was no statistical difference between the study group and controls in terms of gender (p>0.05).
PREVALENCE OF ANTI-HCV IN PATIENTS WITH CLD AND CONTROL
The prevalence of anti-HCV in the study group was 13/90 (14.4%) while that in the controls was 2/85 (2.4%). The prevalence of anti-HCV was significantly higher in patients with CLD than in the controls (p<0.05). , and the other studies outside Nigeria looked at HCV infection in patients with Liver cirrhosis, and HCC. This may account for the disparity in the infection rate of HCV found in the patients studied. However, comparing the prevalence of HCV infection in patients with HCC from Africa, our study (20.5%); Ola et al 10 there appears to be a dichotomy that cannot be explained by differences in sample sizes, environmental factors, sociocultural practices, high risk behaviour, and geographical variation. There appears to be a low rate of HCV infection in Africans with HCC compared with Asians. This may also underscore the regional variation in the burden of HCV infection. Perhaps there are yet unidentified factors in play.
Larger, multi-centered studies are advocated to unravel this mystery.
In conclusion, even though the prevalence of HCV infection is significantly higher in patients with chronic liver disease compared with controls, there is still a low rate of HCV infection among Nigerian patients with CLD.
